Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

Share Price is delayed by 15 minutes
Get Live Data
65.60    0.60 (0.92%)
Bid:
65.60
Ask:
66.00
Spread: 0.40 (0.61%)
Market Cap: £579.53m
IPO Live PriceLast checked at - London Stock Exchange

Intraday Ip Group Share Chart

Share buyback programme update

9 Jan 2025 07:00

RNS Number : 6561S
IP Group PLC
09 January 2025
 

FOR RELEASE ON

9 January 2025

 

 

IP Group plc - Share buyback programme update

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), which invests in breakthrough science and innovation companies with the potential to create a better future for all, is pleased to provide the following update.

Following the receipt of £119m of initial cash proceeds from the sale of portfolio company Featurespace to Visa, the Group previously announced its intention to increase the Group's current share buyback programme (the "Buyback Programme") by a further £25m (the "Buyback Extension"). Together with the up to £15m anticipated to be received from the secondary sale announced on 09 December 2024, this will increase the buyback programme to a total of up to £70m.

The Company is now pleased to announce that it has today launched the £25m Buyback Extension, which will run until 31 December 2025 unless completed or terminated earlier, or unless the Company and Deutsche Numis agree otherwise (in which event an announcement would be made), and, to the extent not completed or terminated before the 2025 Annual General Meeting, conditional on the Company's buyback authority being renewed at such meeting. This follows completion of the £10m share buyback tranche launched in October 2024.

Since commencing the Buyback Programme, the Group has purchased 66,907,021 shares at an average price of 44.828 pence per share for an aggregate consideration of £30m. All shares acquired under the Buyback Programme have been, or will shortly be, cancelled. Following such cancellation, the Company's issued share capital consists of 974,489,255 Ordinary Shares with voting rights and there are no Ordinary Shares held in treasury.

Details of the Buyback Extension

 

For the Buyback Extension, IP Group has entered into a non-discretionary agreement with Deutsche Numis to continue to manage the Buyback Programme on its behalf. Deutsche Numis will make its trading decisions in relation to the Ordinary Shares independently of the Group.

Any Ordinary Shares purchased under the Buyback Extension will be cancelled.

The Buyback Extension is in accordance with IP Group's general authority to purchase a maximum of 102,769,901 Ordinary Shares granted by its shareholders at the Annual General Meeting held on 12 June 2024. The Buyback Programme will continue to be effected within the parameters of the Market Abuse Regulation 596/2014/EU and the Commission Delegated Regulation 2016/1052/EU (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018), including where relevant pursuant to the Market Abuse (Amendment) (EU Exit) Regulations 2019), and in accordance with Chapter 9 of the Financial Conduct Authority's Listing Rules. IP Group confirms that it is not in a closed period and currently has no other unpublished price sensitive information.

Save to the extent they are varied by this announcement, all other parameters outlined in the Company's announcement on 18 December 2023 will continue to apply.

IP Group will continue to make further regulatory announcements to shareholders in respect of purchases of Ordinary Shares by the Group as they occur.

 

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Liz Vaughan-Adams, Communications

+44 (0) 20 7444 0062/+44 (0) 7967 312125

Portland

Alex Donaldson

+44 (0) 7516 729702

 

Notes for editors

 

About IP Group

 

IP Group accelerates the impact of science for a better future. As the most active UK based, early stage science investor, we develop and support some of the world's most exciting businesses in deeptech, life sciences and cleantech (led by Kiko Ventures). Through Parkwalk, the UK's largest growth EIS fund manager, we also back world-changing innovation emerging in leading universities and research institutions. Our specialist investment team combines sector expertise with an international approach. Together we have a strong track record of success, having backed high-profile companies including Oxford Nanopore Technologies plc, First Light Fusion, Hysata, and Oxa. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO. For more information, please visit our website at www.ipgroupplc.com.

 

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCPKFBKFBKDODK
Date   Source Headline
7th Oct 20207:00 amRNSEnterprise Therapeutics' program acquired by Roche
23rd Sep 20201:40 pmRNSHolding(s) in Company
15th Sep 202012:07 pmRNSSecond Price Monitoring Extn
15th Sep 202012:02 pmRNSPrice Monitoring Extension
7th Sep 202012:07 pmRNSSecond Price Monitoring Extn
7th Sep 202012:02 pmRNSPrice Monitoring Extension
1st Sep 20205:18 pmRNSForm 8.3 - Modern Water plc
5th Aug 20207:00 amRNSHalf-yearly results
3rd Aug 20207:00 amRNSNanopore partners with govt on covid-19 test
30th Jul 202012:08 pmRNSSecond Price Monitoring Extn
30th Jul 202012:02 pmRNSPrice Monitoring Extension
29th Jul 20209:45 amRNSHolding(s) in Company
28th Jul 20202:44 pmRNSNotice of Results
14th Jul 20201:29 pmRNSIP Group sells 9.16m shares in Ceres Power
14th Jul 20207:00 amRNSResult of secondary placing in Ceres Power
13th Jul 20205:11 pmRNSProposed secondary placing in Ceres Power Holdings
6th Jul 202012:02 pmRNSPrice Monitoring Extension
6th Jul 20207:00 amRNSAppoints Prof. Clark Chair of ESG Ethics Committee
3rd Jul 202012:07 pmRNSSecond Price Monitoring Extn
3rd Jul 202012:02 pmRNSPrice Monitoring Extension
24th Jun 20202:39 pmRNSHolding(s) in Company
24th Jun 20208:10 amRNSHolding(s) in Company
23rd Jun 202011:37 amRNSLTIP & DBSP awards; Director/PDMR shareholding
18th Jun 20202:05 pmRNSResult of AGM
18th Jun 20207:00 amRNSAGM Statement
9th Jun 20205:47 pmRNSAGM update
5th Jun 20206:28 pmRNSHolding(s) in Company
26th May 202010:05 amRNSInivata receives $25m investment from NeoGenomics
26th May 20207:00 amRNSOxford Nanopore announces £48.4m of new funding
22nd May 20207:00 amRNSOxford Nanopore in development of covid19 test
21st May 20207:00 amRNSIP Group sells 12.25m shares in Ceres Power
21st May 20207:00 amRNSResult of secondary placing in Ceres Power
20th May 20204:48 pmRNSProposed secondary placing in Ceres Power Holdings
19th May 202012:02 pmRNSPrice Monitoring Extension
15th May 20204:36 pmRNSPrice Monitoring Extension
13th May 202012:08 pmRNSSecond Price Monitoring Extn
13th May 202012:03 pmRNSPrice Monitoring Extension
13th May 20207:00 amRNSFeaturespace completes £30m funding round
12th May 202012:02 pmRNSPrice Monitoring Extension
7th May 202012:02 pmRNSPrice Monitoring Extension
29th Apr 20204:57 pmRNSHolding(s) in Company
24th Apr 202012:02 pmRNSPrice Monitoring Extension
16th Apr 20203:45 pmRNSNotice of AGM
8th Apr 20205:04 pmRNSHolding(s) in Company
6th Apr 20205:45 pmRNSHolding(s) in Company
30th Mar 20202:12 pmRNSIssue of Equity
19th Mar 202012:08 pmRNSSecond Price Monitoring Extn
19th Mar 202012:03 pmRNSPrice Monitoring Extension
12th Mar 20209:00 amRNSHolding(s) in Company
11th Mar 20207:01 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.